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Cannabinoids, cannabis and cannabis-based medicines (CBM) are increasingly 
used to manage pain, with limited understanding of their efficacy and safety. 
We assessed methodological quality, scope, and results of systematic reviews 
of randomised controlled trials (RCTs) of these treatments. Several search 
strategies sought self-declared systematic reviews. Methodological quality 
was assessed using both AMSTAR-2 and techniques important for bias 
reduction in pain studies. Of 106 papers read, 57 were self-declared 
systematic reviews, most published since 2010. They included any type of 
cannabinoid, cannabis, or CBM, at any dose, however administered, in a broad 
range of pain conditions. No review examined the effects of a particular 
cannabinoid, at a particular dose, using a particular route of administration, 
for a particular pain condition, reporting a particular analgesic outcome. 
 
Confidence in the results in the systematic reviews using AMSTAR-2 
definitions was critically low (41), low (8), moderate (6), or high (2). Few used 
criteria important for bias reduction in pain. Cochrane reviews typically 
provided higher confidence; all industry-conflicted reviews provided critically 
low confidence. Meta-analyses typically pooled widely disparate studies, and, 
where assessable, were subject to potential publication bias. Systematic 
reviews with positive or negative recommendation for use of cannabinoids, 
cannabis, or CBM in pain typically rated critically low or low (24/25 [96%] 
positive; 10/12 [83%] negative).  
 
Current reviews are mostly lacking in quality and cannot provide a basis for 
decision-making. A new high-quality systematic review of RCTs is needed to 







Available systematic reviews are of insufficient quality adequately to assess 
the evidence of cannabinoids, cannabis, and cannabis-based medicines for 




In 2018 the International Association for Study of Pain established a Task 
Force on the use of cannabinoids, cannabis, and cannabis-based medicines 
(CBM) for pain management. It has four Work Packages (WP) focused on 1) 
basic science and evidence for efficacy in preclinical models [72], 2) evidence 
for clinical analgesic efficacy [28] 3) risk and evidence of harm to the individual 
[31,50], and 4) the societal impact and policy. 
 
This overview review is part of the second WP and is focused on summarizing 
the evidence of efficacy presented in systematic reviews of randomized 
controlled trials (RCTs) of any broadly-defined cannabinoid product in any 
type of pain condition.  
 
There have long been concerns about the quality of most of the medical 
literature [37,68]. A 1996 survey indicated that 90% of meta-analyses had 
methodological flaws that could limit their validity, and that meta-analyses of 
low quality produced significantly more positive conclusions [39]. There has 
subsequently been an epidemic of systematic reviews, with huge growth rates 
in their numbers without any necessary improvement in their quality [68], 
leading to the conclusion that the large majority of systematic reviews and 
meta-analyses are unnecessary, misleading, and/or conflicted. Industry-
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supported meta-analyses have been found to be less transparent, with few 
reservations about methodological limitations of the included trials, and with 
more favourable conclusions than corresponding Cochrane reviews [41]. 
 
Even in good quality Cochrane reviews, the use of Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) to 
summarise the quality of evidence indicates that fewer than 20% of reviews 
actually have any high quality evidence [30]. Only confusion results from the 
product of low quality evidence and low quality systematic review of that 
evidence. High standards in clinical trials and systematic reviews of those trials 
are absolutely essential to improve knowledge, make policy, or make 
individual clinical decisions; anything else is guesswork. 
 
The aim of this overview review of WP2 was therefore to assess the 
methodological quality, scope, reported results of systematic reviews and 
meta-analyses of RCTs of cannabinoids, cannabis, and CBM for pain relief, and 




A protocol for this overview is registered on Prospero (Prospero ID 
CRD42019124710) and published [28]. We followed the Preferred Reporting 
Items for Systematic Review and Meta-Analysis Protocols [49]. A truncated 
report of methods is therefore given here. 
 
2.1 Systematic reviews for inclusion 
 
We chose to include any review whose authors defined as a systematic review 
of RCTs, although definitions of what comprises a systematic review are 
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considerably more restrictive [34]. The intention in the protocol was to analyse 
only high quality evidence found in Cochrane Effective Practice and 
Organisation of Care [25] GRADEs of evidence as high or moderate quality, 




We included systematic reviews of RCTs involving people of any age with any 
form of acute and chronic pain, including pain secondary to another 
condition, such as pain with spasm, multiple sclerosis (MS), or leg cramps. 
Experimental pain was not included. 
 
2.3 Interventions and comparators 
 
We included any type of cannabinoid product (natural or synthetic), cannabis, 
or CBM, by any route of administration, at any dose, and with any comparison 
intervention. This included endocannabinoid system modulators such as fatty 
acid amide hydrolase (FAAH) inhibitors and N-paltmitoylethanolamide (PEA). 
For inclusion, systematic reviews were required to examine interventions to 




A range of primary and secondary outcomes were proposed in the protocol. 
The limited nature of systematic reviews included meant that this overview 




2.5 Search and selection of systematic reviews 
 
We searched PubMed, EMBASE, DARE, and the Cochrane Controlled Register 
of Trials (CENTRAL) for systematic reviews of cannabinoids, cannabis, and CBM 
and for people with pain. The main search was completed in August 2019. 
Bibliographies of included and excluded reviews were examined for possible 
reviews, and electronic citations of PubMed and Google Scholar also 
examined. We conducted targeted searches for further systematic reviews 
through additional electronic searches, through reference lists of retrieved 
articles and reviews, or through other sources up to January 2020. Two 
authors independently sifted the titles and abstracts identified, with a third 
author resolving disagreement.  
 
2.6 Data extraction 
 
Data extraction was conducted by two authors (RAM & EF) and checked by 
others; disagreement was resolved by consensus (initially discussion with CE, 
but wider if needed). The following information was extracted from each 
review:  
1. Review characteristics, e.g., design, participants, age and sex, pain 
condition, inclusion/exclusion criteria, risk of bias method. In addition, 
we sought information related to Assessment of Multiple Systematic 
Reviews (AMSTAR)-2 [67], methodological issues related to known 
sources of bias in pain studies, use of GRADE, and GRADE assessment if 
used. We extracted the number of trials and patients used in 
assessment of pain, the number in randomised trials, and the number 




2. Intervention and comparator characteristics, e.g., type of cannabinoid, 
dose, route of administration, comparator. 
3. Outcomes listed in the primary outcomes. 
 
In addition, we made a judgement on the strength of any recommendation 
made by authors in the review abstract. This was done by RAM and EF, 
discussed initially with CE, and then wider if needed. Judgements were based 
on being positive (recommended use), equipoise (a balance of evidence), or 
negative (recommended non-use), or no statement. Strength was judged as 
strong (e.g. provide reasonable therapeutic option, should not be used), 
moderate (e.g. moderately effective, no unbiased evidence), or weak (e.g. 
small analgesic benefit, more trials needed to support).  
 
2.7 Assessment of review quality and validity 
 
We assessed each included review using AMSTAR-2 [67]. Two authors 
assessed each review using the criteria with disagreement resolved by 
consensus.   
 
We also conducted additional validity checks of potential critical importance 
in the evaluation of analgesic efficacy. These included: 
 
• Did the review use a defined diagnostic criterion for pain conditions? 
• Did the reviews include only studies in which patients made their own 
assessment of pain? (professional and patient assessment often 
disagrees, with professionals significantly underestimating pain [66]). 
• Did the reviews use studies with defined minimum pain intensity of 
moderate or severe pain? (mild pain can reduce the sensitivity of trials 
to demonstrate an analgesic effect). 
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• Did the reviews examine study size as a confounding factor in any 
analysis of efficacy? (systematic reviews have been criticised for being 
over-confident of results with inadequate data [2,65,79]; there is 
increasing evidence of the importance of small trial size, both because 
of random chance [16,52,76], and as an important source of bias 
[22,23,26,36,57].  
• Did the review examine susceptibility to publication bias? (if possible, 
for each review with dichotomous numerical data we will assess the 
likelihood of publication bias [51]). 
 
2.8 Data synthesis and/or descriptive evaluation of reviews 
 
We planned to evaluate strengths and weaknesses of systematic reviews of 
cannabinoids in treating pain by a descriptive analysis, and meta-analysis if 
appropriate. As there was little high quality evidence found, and none useable 
for meta-analysis, the descriptive analysis of all systematic reviews became the 
only mechanism of evaluation. 
 
The absence of combinable data did not preclude unplanned evaluations, 
including links between AMSTAR-2 score matched critical methodological 
criteria for evaluation of analgesic efficacy, the potential impact of reviews 
using Google Scholar citation numbers, judgement on the strength of 
recommendations by review authors based on language in the abstracts, 
numerical assessment of analgesic efficacy, and how these factors interacted. 
 
The nature of the reviews precluded any useful independent assessment of 





3.1 Results of search 
 
Initial electronic searching found 685 possible systematic reviews, reduced to 
559 after removal of duplicates. After reading the abstracts 106 papers were 
obtained in full, and read for possible inclusion as a systematic review. Forty-
nine were excluded (Appendix 1 lists the reasons and references). Reasons for 
exclusions were: 
 
• 12 were narrative or scoping reviews; 
• 11 were practice guidelines, position papers, or therapeutic 
recommendations; 
• 8 were overview reviews; 
• 2 each were not systematic reviews, had no pain outcomes; did not 
investigate cannabinoids, were duplicates, were older versions of 
updated systematic reviews, or were thesis chapters not relevant to this 
overview; 
• 1 each was a clinical trial, a review of consensus statements, 
investigated placebo only, investigated experimental pain, investigated 
adverse events, or investigated combination therapies without 
cannabinoids alone.  
 
Fifty-seven [3,5-15,17,19-21,24,27,29,32,33,35,38,40,42-48,54-56,58-64,69-
71,73-75,77,78,80-87] were included in this overview review as systematic 
reviews investigating cannabinoids, cannabis, or CBM in RCTS with pain as an 
outcome (Appendix 2 gives information on date of publication, pain or other 
condition examined, type of CBM investigated, route of administration, and 
abstract conclusion). Seven were Cochrane reviews [5,10,15,54,59,64,82], and 
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six reported either financial sponsorship from a pharmaceutical company or 
were conflicted because authors were employees of a company with interests 
in cannabinoids [8,38,46,69,70,71].  
 
Forty-seven reviews specifically examined pain (10 neuropathic pain, 10 any 
type of pain, 8 chronic non-cancer pain, 7 cancer pain, 4 rheumatic pain, 2 
fibromyalgia, 2 spinal cord injury, 1 acute pain, 1 pain in children, 1 HIV 
neuropathy, and 1 phantom limb pain). Ten reviews considered conditions in 
which pain was one of several symptoms (5 muscular dystrophy, 3 
neurological conditions, 1 leg cramps, and 1 gastrointestinal conditions). 
 
3.2 General description of included studies 
 
Included studies were mostly published recently. The earliest was published in 
2001 [17] and the most recent in 2019 [13,33,56,63,86]. Only five were 
published before 2010; most (90%) were published since 2010 (Figure 1), and 
two-thirds of the included reviews had been published in the past five years 
 
Summary information on these 57 systematic reviews is shown in Table 1, 
organised by pain condition. As several of these systematic reviews examined 
a wide range of medical conditions, only the information involving pain and 
cannabinoids is shown. 
 
Neuropathic pain, chronic non-cancer pain, all pain, and cancer pain 
predominated, but 15 distinct areas were recognised. Some were not classic 
pain conditions, for example pain associated with spasm in MS or leg cramps. 
 
The number of studies and patients involved, the number of randomised trials 
included, and the number available for any statistical analysis varied widely 
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between reviews and pain conditions. For six pain conditions there were no 
available data for analysis. Some reviews in some conditions analysed data 
from several thousand patients. For example, Yanes et al [86] analysed data 
from 25 trials and 2,248 patients in a meta-regression for all pain conditions, 
and Torres-Moreno et al [77] pooled data from 2,692 patients in 11 MS trials. 
The variation in numbers between reviews in apparently the same condition 
reflected different approaches in analysing drug and formulation, route of 
administration, and whether a broad or narrow approach to type of condition 
was used (for example, painful diabetic neuropathy rather than all neuropathic 
pain). 
 
Risk of bias was assessed in 45 of the 57 reviews, predominantly using 
Cochrane risk of bias tools (27), the Oxford quality scale (13) or a modification 
of it (3), an American Academy of Neurology tool (1) or a Physiotherapy 
Evidence Database tool (1). Twelve systematic reviews made no apparent 
mention of formal risk of bias assessment [8,11,12,20,42,60,62,78,80,85-87]. 
3.3 Cannabinoid used and route of administration 
 
Reviews examined the effects of a wide range of cannabinoid drugs or 
preparations, though these were seldom clearly defined. The most common 
definition was ‘cannabinoid’ in 36 reviews, ‘any cannabis preparation’ in eight, 
‘plant-based cannabis preparation’ in six, two each examined nabilone, 
dronabinol, or nabiximols, two PEA derivatives, and one each 9-
tetrahydrocannabinol (THC), cannabidiol, and Cannabis sativa. Appendix 3 
shows their use by pain condition. 
 
Route of administration was generally not defined (36 reviews), or ‘any route’ 





3.4 Pain outcome used in systematic reviews 
 
Few reviews clearly defined an outcome of at least 30% or 50% pain intensity 
reduction considered by patients to be a good outcome [53](Appendix 5 for 
results according to pain condition); only 14 reviews (25%) sought these 
outcomes. Most, 28 reviews, did not define an outcome. The remaining 
reviews used some calculation based on continuous variables, mostly 
standardised mean difference or mean difference (10 reviews), effect size (3 
reviews), or other (2 reviews). Three-quarters of the reviews therefore made no 
prior adjudication of what a successful outcome might be or justified the 
choice of outcome. 
 
3.5 Use of GRADE 
 
GRADE evaluation of overall evidence certainty was used in 17 systematic 
reviews, and not used in 40. Of the 17 that used GRADE, 13/17 (76%) included 
very low certainty; the ratings were: 
 
0 high certainty,  
4 moderate certainty,  
1 moderate or very low certainty, 
3 low certainty, 
2 low or very low certainty, 
7 very low certainty. 
 




Each review was judged according to the 16-criterion AMSTAR 2 list; Appendix 
6 shows scoring for individual reviews. The results (Table 2) showed that only 
four of the criteria were met by more than half of the reviews (showing some 
detail of included studies (85%), conflict of interest reporting (81%), study 
selection in duplicate (65%), and data extraction in duplicate (56%)). 
 
Meeting some criteria was not applicable. For example, as many reviews had 
few studies, with those studies often small and clinically heterogeneous, no 
meta-analysis was appropriate. That situation made it difficult to discuss risk 
of bias or heterogeneity on the result. It was also difficult to judge whether 
risk of bias was satisfactory. In addition, the AMSTAR criterion for a 
comprehensive literature search demanded searches of grey literature, 
consulting experts in the field, and searching of trial registries. One review met 
all those criteria [13], and 53 reviews partially met the criteria for a literature 
search, typically not searching grey literature. 
 
Other criteria met uncommonly were a study design explanation (no reviews), 
reporting on sources of funding of studies (19 reviews), production of a 
complete PICO (Patient, Intervention, Comparison, Outcome; 13 reviews), 
assessment of small study bias (14 reviews), and prior publication of a 
protocol (17 reviews). 
 
The failure to meet critical and non-critical AMSTAR criteria resulted in 
generally low assessments of overall confidence in the results of the review. 
Using the AMSTAR definitions, confidence in the results of 86% of the reviews 
was critically low (41 reviews) or low (8 reviews). For six reviews was 
confidence in the results moderate, and for only two was it high; only 1 in 7 




For the seven Cochrane reviews overall confidence was high or moderate in 
four, and low in three; none was critically low. All six conflicted reviews were 
assessed as having critically low confidence (Figure 2). Of the 12 reviews not 
specific for pain, nine were evaluated as critically low, and three of low 
confidence. 
 
Appendix 7 shows AMSTAR confidence assessments in the results of the 
reviews according to the pain condition investigated. 
 
3.7 Use of critical criteria for assessment of analgesic efficacy 
 
Because AMSTAR is a generic instrument not specifically designed for use with 
analgesic studies, we also assessed the systematic reviews for the use of 
methodologies designed to avoid significant biases in pain trials (Appendix 6 
for individual result scoring and Appendix 8 for summary results by pain 
condition). The results for this assessment demonstrated that methods used 
to minimise bias in analgesic studies were typically not used (Figure 3). 
 
Only half of the reviews specified using trials that were both properly 
randomised and properly double blind. About 10% or fewer required patient 
reported pain only, performed any sensitivity analysis for small trials, 
evaluated sensitivity of a result to publication bias, used studies where 
entrants were required to have pain with a minimum pain intensity, or 
evaluated the potential impact of imputation method for missing data. 
 
Results for the seven Cochrane reviews overall confidence were mixed. Three 
from a pain-specific group used only randomised and double blind studies 
and met 50% or more of the criteria. The other four accepted studies that 
were not necessarily randomised or double blind and met 25% of criteria or 
 
 16 
fewer. Four of the six conflicted reviews used only randomised and double 
blind studies and met 38% or fewer of the criteria. Of the 12 reviews not 
specific for pain, only four used randomised and double blind studies and 11 
met 25% or fewer of the criteria. 
 
3.8 Concordance between AMSTAR and critical pain criteria 
 
Thirty-seven of the 39 (95%) reviews with AMSTAR ratings of critically low met 
two or fewer of the eight critical pain criteria compared with 5/8 (63%) rated 
low, and 2/7 (29%) of those rated moderate or high. There was a tendency for 
higher scores in reviews with AMSTAR rating of moderate or high (Table 3). 
 
A few individual reviews stood out against the trend. For example, Finnerup et 
al [27] had a critically low AMSTAR rating, but met six of eight critical pain 
criteria, while Brettshneider et al [15] had a high AMSTAR rating but scored 
only one of eight criteria. Results of the three Cochrane reviews from a pain-
specific group scored reasonably well on both.  
 
3.9 Impact of systematic reviews 
 
We examined the impact of the 54 of the 57 systematic reviews by looking at 
the number of citations for each as reported by Google Scholar on Sept 20 
2019; three 2019 publications were identified after that date, and would have 
had few if any citations. The 54 reviews had been cited a total of 6760 times 
(mean 125 citations, median 47 citations), with about 1100 citations a year 




The majority of citations came for a small number of systematic reviews 
(Figure 4). Two reviews were cited on average over 200 times a year [27,84], 
and three other reviews were cited between 50 and 100 times a year [5,42,54]. 
Because most reviews had been published within a limited period, no effect of 
recency in citation rate was discernible. 
 
There was no consistency as why these five were particularly heavily cited. 
Table 4 summarises information on these reviews, with possible reasons for 
their high citation rate. 
 
3.10 Judgement on abstract strength of recommendation 
 
Abstracts of systematic reviews typically provide some comment on the 
strength of evidence or the direction of any effect, and frequently both. These 
can be interpreted as recommendations or are frequently framed as 
recommendations. We made a judgement as to whether the implied 
recommendation in an abstract was positive or negative (strong, moderate, or 
weak), or showed equipoise, or whether there was no recommendation 
relating to the use of cannabinoid-based medicines for treatment of pain. 
Table 5 shows examples of how we made these judgements, with details of 
each in Appendix 7. 
 
Of the 44 systematic reviews making a recommendation, 27 were moderate or 
strong, 10 weak, and 7 indicated equipoise. Of the seven Cochrane reviews, 
three had no opinion, two were strong negative, one at equipoise, and one 
was weak positive. Of the six conflicted reviews, three had no opinion, one was 
weak positive, and two were strong positive. Eight of the 19 reviews with 
moderate or strong positive recommendation had no formal risk of bias 
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assessment [8,11,12,20,42,60,61,86]. All reviews making weak 
recommendations had a risk of bias assessment. 
 
3.11 Relationship between abstract strength of recommendation, AMSTAR rating, 
and critical pain criteria 
 
Table 6 shows the AMSTAR rating and critical pain criteria score. Systematic 
reviews with any positive recommendation of use of cannabinoids, cannabis, 
or CBM in pain typically rated critically low on AMSTAR (20/25; 80%) or 
critically low or low (24/25; 96%). They typically used two or fewer of the eight 
critical pain criteria to avoid bias. Reviews with negative recommendations 
were somewhat less likely to have a critically low (6/12; 50%) or critically low 
or low rating (10/12; 83%), and used three or more critical pain criteria.  
 
Reviews making weak positive or negative recommendations were more likely 
to use more critical pain criteria than those making moderate or strong 
recommendations. 
 
3.12 Calculation of magnitude of analgesic effect 
 
Seventeen systematic reviews used numeric data to calculate the magnitude 
of any analgesic effect, for a variety of interventions, routes of administration, 
and painful condition, using a range of different pain outcomes and statistical 
outputs (Table 7). Analyses were conducted on data sets that varied between 
1 and 25 trials, and 22 and 2692 patients. No analysis was conducted on a 
defined intervention, defined dose or intensity, or defined route of 




Ten of 18 reported results showed statistical difference from placebo, while 8 
showed no difference. Statistical significance was associated with positive 
abstract recommendation, while no significance was associated with negative 
abstract recommendations.  
 
Table 7 also shows AMSTAR-2 confidence level and the number of points 
scored for critical pain elements. Statistical significance was generally 
associated with critically low AMSTAR assessment and 3/8 or fewer pain 
criteria. The exception was a review of short-term (six hours to five days) 
effects of inhaled or smoked cannabis in small number of patients with 
chronic pain conditions in trials with significant risk of bias [7].  
 
Reviews without statistical significance generally made no recommendation or 
a negative recommendation, with a tendency to higher AMSTAR grades and 
higher scores for critical pain elements. Exceptions were Stockings et al [74] 
with bare significance for one outcome, and Phillips et al [61] which included 
only 89 patients. 
 
A calculation of the susceptibility to publication bias from studies with null 
results was based on an NNT of 10 or greater being clinically not relevant [51]. 
No calculation was possible where there was no statistical significance (NNT is 
then essentially infinity), or for reviews reporting continuous outcomes. For 
only three of these reviews were data available that allowed for the 
calculation. The number of people in trials with null results required to 
overturn the statistically significant results for cannabinoids was 213 in 






To the extent that any conclusions can be drawn from existing systematic 
reviews, they can only be made with respect to the types of cannabinoid, 
cannabis, and CBM investigated to date, in the specific patient groups and 
pain types studied.  No conclusions with respect to other interventions yet to 
be tested are possible. 
 
Of the many reviews of the effects on pain of studies concerning 
cannabinoids, cannabis, and CBM published to the end of 2019, 57 claimed to 
be systematic reviews. The Cochrane Handbook lists five key characteristics of 
a systematic review [34]: a clearly stated set of objectives, explicit and 
reproducible methods, systematic and comprehensive searches, assessment of 
validity of results including risk of bias, and a systematic presentation of those 
results. While relatively few of the 57 systematic reviews examined here would 
meet these criteria, the cachet of a review claiming to be systematic is such 
that all required examination.  
 
Included reviews examined 15 distinct pain areas. Most accepted any type of 
cannabinoid, at any dose, by any route of administration, though some had a 
more defined scope. No review examined the effects of a particular 
cannabinoid, at a particular dose or dose range, given by a particular route of 
administration, for a particular pain condition, and reporting a particular 
analgesic outcome.  
 
The degree of pooling for any effect calculations could be extreme; for 
example, one review of cannabinoids in chronic pain pooled data from trials 
as short as six hours, and as long as 15 weeks [57]. Almost 80% of the reviews 
failed to define what a successful outcome might be; rather than defining a 
measure that is important to patients [54], the approach was to make 




Judging systematic review quality is difficult. Most often used methodology is 
AMSTAR, and we used the most recent version, AMSTAR-2 [67]. This is a 
generic tool examining what is regarded as best practice in systematic review 
methodology. The 16 items are themselves not controversial, though judging 
whether a review meets a particular criterion is often subjective, open to 
disagreement between assessors because details of methods may be omitted 
from publications for reason of space. An AMSTAR-2 score probably 
represents a “worst case”. No single criterion was met by more than 50% of 
the reviews, and confidence in the results of 86% of the reviews was critically 
low (41 reviews) or low (8 reviews). This is similar to an assessment of 
systematic reviews in back pain where 74% rated critically low and 16% low 
[4]. 
 
A generic approach to quality is of limited value in assessing analgesic effects, 
because it does not examine criteria known to be associated with considerable 
bias in pain trials. We examined eight of those with established association 
with risk of bias, and again few reviews used them. Randomisation and 
blinding were defined criteria in just over half of the reviews, but five of the 
eight criteria were used by 10% or fewer of the reviews. Reviews with low 
AMSTAR-2 rating typically used few pain-associated risks of bias, while those 
providing moderate or high confidence used more.  
 
The implication is that significant sources of potential bias were likely to have 
affected results from most of the 57 systematic reviews. Cochrane reviews 
tended to be better, especially more recent reviews, while conflicted 




Quality was not associated with the impact of reviews as judged by annual 
citation rates on Google Scholar. Three of the top five cited reviews met many 
pain criteria (though not necessarily AMSTAR); the strength of 
recommendation in the abstracts of these reviews was weak negative or none. 
Two were rated critically low confidence by AMSTAR and used very few 
important criteria for avoiding bias in pain studies and reviews (Table 4); their 
strength of recommendation was moderately or strongly positive.  
 
Of the 17 reviews attempting a numerical calculation of the magnitude of the 
analgesic effect, nine had a positive and five a negative recommendation. 
Reviews with positive recommendations were associated with a statistically 
significant analgesic effect, but not reviews with negative or no 
recommendation. Susceptibility to publication bias for three reviews with 
statistical significance showed that the result would have been overturned by 
a null result from a clinical trial of 100-250 patients. Moreover, eight of 19 
reviews with moderate or strong positive assessment, statistical significance or 
no, did not evaluate risk of bias, whereas all making a negative 
recommendation assessed risk of bias. 
 
To summarise, what we have is a body of work that tells us little about 
whether any particular cannabinoid or cannabis-based treatment tested to 
date, at a particular dose and route of administration, given to someone with 
a particular form of pain could lead to a particular degree of pain reduction (at 
least 50% pain intensity reduction or reduction of pain to just mild [54]). Low 
quality reviews do no more than suggest there may be, while the highest 
quality say probably not. 
 
It is telling that a US National Academies of Sciences, Engineering and 
Medicine report on therapeutic effects of cannabis and cannabinoids, and a 
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later update [1,18], concluded that there is “substantial” evidence that 
cannabis is an effective treatment for chronic pain in adults. The committee 
included experts in substance abuse, cardiovascular health, epidemiology, 
immunology, pharmacology, pulmonary health, neurodevelopment, oncology, 
pediatrics, public health, and systematic review methodology, but not pain. It 
based much of its findings on pain on the systematic review of Whiting et al 
[34]. That review was given an AMSTAR rating of critically low confidence and 
used only 2/8 pain methodologies. Moreover, for the patient-orientated 
outcome of at least 30% pain intensity reduction it reported a result not 
significantly different from placebo, including, as it did, no significant 
difference in the 95% confidence interval (odds ratio 1.41 (0.99 to 2.00)). That 
conclusion should be revisited, revised, or retracted, as it is significantly 
misleading. 
 
There are several lessons: 
 
1. The label of systematic review does not itself confer value for pain. 
Generic scoring systems for systematic reviews provide limited 
confidence, and the best mechanism to ensure that a systematic review 
provides a robust and reliable answer is to combine generic Cochrane 
approaches with pain specific criteria, as several Cochrane review 
groups do. Systematic reviews of cannabinoids, cannabis, and CBM in 
pain require authors skilled not only in systematic review methodology 
but also those knowledgeable about pain and cannabinoids. 
2. Clinical trials to measure analgesic effect have a long-established basic 
methodology, but recent decades have demonstrated additional 
situation-specific factors needing consideration. Trials need to be 
conducted to the highest standards (especially those for registration or 
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marketing purposes) and provide outcomes of clinical as well as 
statistical relevance to both efficacy and harms.  
3. RCTs investigating cannabis, cannabinoids, and CBM and pain should 
be designed to include well-defined populations with specific pain 
diagnoses, evaluate particular interventions (specific cannabinoid, 
doses, route of administration) and comparators, and report on 
meaningful patient reported pain outcomes (including functional 
outcomes and not just analgesic efficacy). Good RCTs can be 
complemented by patient registries to gather data on long-term 
patient outcomes to explore effectiveness of cannabinoids, cannabis 
and CBMs for the treatment of pain and function in real life. 
4. More details of the clinical trials should be provided in reviews, 
particularly relating to concomitant analgesic medication, previous use 
of cannabinoids and other analgesics, and whether testing has been 
conducted to exclude non-trial use of drugs in test or placebo arms.  
5. The fact that on AMSTAR-2 alone, 41 systematic reviews providing 
critically low confidence in their results were published in medical 
journals (including some prestigious journals) indicates a potential 
problem with research quality. It is debatable whether this is a failure of 
journals and the peer review system, or whether scoring systems are 
unrealistic and penalise reviews unnecessary. Does a literature search of 
grey literature actually improve systematic reviews of RCTS, for 
example? 
6. Low quality and over-claiming positive benefits have long been 
associated [37,39]. There is no obvious sign of improvement, and that is 
a matter of considerable concern. 
7. The link between the low quality of reviews and the positive or negative 
assessment of analgesic efficacy in review abstracts (often the only part 
that is read in any detail, or at all) is of concern. It begs the question 
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not of challenge to these reviews, but to whether the implications are 
such as to consider calls for retraction. A Cochrane review 
compromised by methodological faults would likely be retracted, 




The primary reasons for this overview review were to examine the quality of 
the extant review literature and question whether a new systematic review 
would be needed. The results of the overview demonstrate that most reviews 
are lacking in quality and cannot provide a basis for decision making. In the 
circumstances, a new systematic review adhering strictly to methodological 
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Figure 1: Rate of publication of 54 included systematic reviews 
 
Number of systematic reviews on cannabinoids, cannabis, or CBM published 
each year between 2001 and 2019. No systematic review was published before 
2001. 
 
Figure 2: AMSTAR evaluation of confidence in results of systematic reviews 
 
 
AMSTAR-2 evaluations as percentages of 57 systematic reviews, seven 
Cochrane reviews, and six conflicted reviews with industry sponsorship 
 
Figure 3: Percentage use of criteria designed to minimise bias in analgesic 
trials 
 
Percentage of reviews using criteria designed to minimise bias in analgesic 
trials (LOCF: last observation carried forward; BOCF: baseline observation 
carried forward) 
 
Figure 4: Distribution of total citations and total publications according to annual 
rate of citation 
 
Distribution of the percentage of total citations and total reviews according to 
the average number of citations per year for each review calculated from the 
number of Google Scholar citations divided by the number of years since 
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publication. A small percentage of reviews accounted for the largest 
percentage of citations 
 
 
